The PCSS-MOUD Exchange is a four-session course focused on the implementation of prescribing medications for treating opioid use disorder (MOUD) in a variety of healthcare settings. PCSSMOUD-X is intended for an interprofessional audience. Prescribers with frontline experience prescribing MOUD and developing clinic workflows will be available during all four sessions to answer participants’ questions and discuss real-world cases.
The PCSS-MOUD Exchange four-session series is scheduled to begin on Thursday, April 4, 2024. The series will consist of four weekly sessions, held every Thursday at 3:00 p.m. EST. To learn more about each session and register, please follow the links below (coming soon). Mark your calendar and plan to join us starting April 4th! We look forward to seeing you there!
Exchange Session 1 – Explore
April 4, 2024 at 3:00pm
Topic: Review medications for opioid use disorders (MOUD), with a focus on buprenorphine treatment and its various formulations, and strategies for including harm reduction approaches into care. Discuss administrative, clinical and financial considerations, and provide resources for both prescribers and non-prescribers.
Exchange Session 2 – Prepare
April 11, 2024 at 3:00pm
Topic: Review patient screening considerations and discuss how OUD screening can be integrated into current clinic workflows. Discuss the training and certifications required for specific team members to implement MOUD. Highlight the critical role of Champions, and how to strategically select Champions to support MOUD implementation.
Exchange Session 3 – Implement/Sustain
April 18, 2024 at 3:00pm
Topic: Review considerations for MOUD initiation and follow-up, including lab guidelines, and clinical management of patients with continued use (e.g., fentanyl, novel synthetic opioids), overdose risk, poly-substance use, and comorbid mental health conditions.
Exchange Session 4 – Implement/Sustain
April 25, 2024 at 3:00pm
Topic: Consider approaches to sustain MOUD and ensure continued access to high-quality care for our most challenged patients, including those who are pregnant, youth/adolescents, those with acute or chronic pain, and those electing to taper their dose.
